Biogen presents additional results from Phase 1b study of salanersen

Biogen (BIIB) presented additional results from the Phase 1b study of salanersen, an investigational novel antisense oligonucleotide given once a year for spinal muscular atrophy, at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. The study evaluated salanersen in children who had suboptimal clinical status despite prior administration of gene therapy. Salanersen was generally well-tolerated. Participants experienced a slowing of neurodegeneration and functional improvement, including achievement of new World Health Organization motor milestones, following initiation of salanersen. These new results include a minimum of one year of follow-up for all participants, building on the interim study data presented at Cure SMA 2025. The company also presented the study designs of the Phase 3 salanersen clinical trials.